Richard Pazdur (Flatiron Health via YouTube)

Ed­i­to­r­i­al: Did Rick Paz­dur's big 'no' on Lil­ly's Chi­na-born PD-1 al­so spell the end for price dis­rup­tion?

Eli Lil­ly has a big de­ci­sion com­ing Thurs­day as an FDA ad­vi­so­ry com­mit­tee con­sid­ers the mer­its of PD-1 block­er sin­til­imab, a drug de­vel­oped in Chi­na with part­ner In­novent. That ad­comm could swing ei­ther way — but if FDA on­col­o­gy head Rick Paz­dur’s word reigns supreme, sin­til­imab is al­ready dead in the wa­ter.

Paz­dur and FDA in­sid­ers think they have a com­pelling case against sin­til­imab for one rea­son: The drug’s piv­otal tri­al was con­duct­ed in Chi­na alone with re­sults that might not trans­late in­to a more het­eroge­nous US pa­tient pool.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.